Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with positive strongyloides larva in the stool~Exclusion Criteria:~* Pregnancy~* Lactating women~* Known allergy to any study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole (Type: ACTIVE_COMPARATOR): Albendazole for 7 days
- ivermectin (Type: EXPERIMENTAL): ivermectin 200 mcg/kg single dose
- ivermectin 2 doses (Type: EXPERIMENTAL): ivermectin 200 mcg/kg two doses in 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).